Cyclophosphamide News and Research

RSS

Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

Results of high-impact clinical trials could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

Younger patients with specific genetic subtypes of non-GCB DLBCL, called MCD and N1, had an exceptional response to the treatment combination.

5 Nov 2021

Elevated allostatic load may impact treatment completion and breast cancer survival outcomes

Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer, according to results presented at the 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held online October 6-8, 2021.

6 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

The first randomized study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months.

20 Sep 2021

'Cold' tumors can be turned 'hot' with extremely low doses of radiation, study shows

A Ludwig Cancer Research study conducted in both mice and a small group of patients with advanced cancers has shown that so-called “cold” tumors that are nearly devoid of immune cells—and therefore unresponsive to immunotherapy—can be turned “hot” with extremely low doses of radiation and the rational use of existing therapies.

9 Sep 2021

Three new guidelines released for treatment and management of systemic vasculitis

The American College of Rheumatology, in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis.

9 Jul 2021

Combination of anti-HER2 breast cancer therapy and checkpoint inhibitor provides no benefit

Adding an immune checkpoint inhibitor to anti-HER2 treatment in breast cancer does not improve pathological complete response (pCR), according to the primary analysis of the IMpassion050 trial presented today during the ESMO Virtual Plenary.

18 Jun 2021

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of lymphocytes, and a large proportion of patients are either unresponsive or develop resistance towards R-CHOP—the standard treatment regimen.

8 Mar 2021

Combination therapy places no greater burden on early-stage breast cancer patients

Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows.

10 Dec 2020

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

7 Dec 2020

Clonal hematopoiesis can confer a health benefit in allogeneic transplants

Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don't have cancer.

7 Dec 2020

New combination treatment for recurrent ovarian cancer shows positive outcomes

A team from Roswell Park Comprehensive Cancer Center has detailed striking findings on the effectiveness of a previously untried combination of old and new drugs as treatment for recurrent ovarian cancer.

19 Nov 2020

High-impact clinical trial results could improve kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online during ASN Kidney Week 2020 Reimagined October 19-October 25.

23 Oct 2020

Researcher is exploring safer and more effective treatment for leukemia

A potentially safer, more effective chemotherapy treatment for patients with blood-related cancers, such as leukemia, who need a particular bone marrow transplant procedure is under study at the University of Arizona Health Sciences.

4 Aug 2020

Novel compound shows promise for ANCA-associated vasculitis

ANCA-associated vasculitis (AAV) is a systemic disease involving the formation of special autoantibodies (so-called anti-neutrophil cytoplasmic antibodies/ANCA) and vascular inflammation.

8 Jun 2020

Drug combo for untreated CLL approved by FDA based on E1912 trial

Patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma now have a new treatment option--a combination of the targeted agent ibrutinib with the immunologic agent rituximab.

29 Apr 2020

Immunotherapy before surgery may help eradicate high-risk breast cancer

A new study led by Yale Cancer Center researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.

28 Apr 2020

Study provides new evidence about optimal way to treat BRCA carriers with breast cancer

Commonly known as the breast cancer genes, the BRCA gene family plays a role in repairing damaged DNA. Inherited mutations in the genes BRCA1 or BRCA2 raise the risk of developing breast, ovarian, prostate and other cancers.

5 Mar 2020

Catastrophic macropinocytosis may aid in cancer treatment

In laboratory experiments, a metabolic inhibitor was able to kill a variety of human cancer cells of the skin, breast, lung, cervix and soft tissues through a non-apoptotic route -- catastrophic macropinocytosis.

18 Dec 2019